Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers

Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.

By · Published June 25, 2026 at 02:02 UTC · Updated July 7, 2026 at 13:22 UTC

8sources
8articles
6velocity
+0%since first seen
66d agofirst detected

Evidence dossier

Intelligence passport

72/100 Excellent
8distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 6.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.
  5. Outcome review added Archynetys revisited the signal after coverage cooled.

Source diversity sample: marketscreener.com · FirstWord Pharma · The Business Journals · citybiz · Law360 · TradingView · BioSpace · Fierce Biotech.

How this dossier is built: methodology · AI policy · corrections.

📍 Aftermath

Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and planned to put substantially all assets for sale. Eli Lilly and Astellas emerged as buyers, with stalking horse sales set at $50 million for Lilly and up to $50 million for Astellas.

Epilogue added 52d ago, after coverage quieted.

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Sangamo Therapeutics has filed for bankruptcy and plans to sell substantially all of its assets. The company has lined up Eli Lilly and Astellas as potential buyers. Lilly is set to acquire assets worth $50 million, with Astellas potentially acquiring assets worth up to $50 million.

Coverage emphasizes the strategic moves by Lilly and Astellas to acquire Sangamo's assets. Reports from FirstWord Pharma, The Business Journals, BioSpace, and Fierce Biotech highlight the bankruptcy filing and the asset sale process. Law360 and TradingView provide details on the Chapter 11 filing and the stalking horse sales.

What to watch next: The outcome of the asset sale process. Coverage does not yet specify the timeline for the completion of the sales or any regulatory approvals that may be required.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 64d ago.

Sources (8)

Quick answers

Why is Sangamo Therapeutics filing for bankruptcy?

Coverage does not yet specify the reasons behind Sangamo Therapeutics' bankruptcy filing.

What assets are Lilly and Astellas acquiring from Sangamo?

Coverage does not yet specify the exact assets being acquired by Lilly and Astellas from Sangamo.

What is the timeline for the completion of the asset sales?

Coverage does not yet specify the timeline for the completion of the asset sales.

Topics

Sangamo Therapeutics bankruptcy Eli Lilly Astellas biotech asset sale

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →